Interleukin-6 (IL6) has been recently reported to contribute to the chemoresistance of pediatric AML [23], and we showed the overexpression (log2 = 3.3) of IL6 after 24 h treatment (Figure 3C). The gene discussed is IL6; the disease is acute myeloid leukemia.